Out of Reach: Understanding Resource Barriers to Gene Therapy for Pediatric Patients With Sickle Cell Disease
Colleen Kelly(Boston Children's Hospital), Kira Bona(Harvard University), Kristine Karvonen(Fred Hutch Cancer Center), Puja J. Umaretiya(The University of Texas Southwestern Medical Center), Sunyu Kang(Harvard University), Leanne Duhaney(Boston Children's Hospital), Mckenzie Griffin(Harvard University), Natasha M. Archer(Boston Children's Hospital), Morgan A. Paul(Dana-Farber Cancer Institute), Sharl Azar(Harvard University), Callie Fry(Harvard University), Erica Esrick(Harvard University), Rahela Aziz‐Bose(Harvard University)
Cited by 0
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
|Journal of Clinical Oncology|2016|754
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|679